<p>自 2020 年初以来，礼来（NYSE: LLY）的股价图呈直线上升趋势，上涨了 553%，目前交易价为 848.74 美元。</p>
<p>该公司成立于 1876 年，但直到 1952 年才上市，但在过去的 4 年中，礼来的市值从 1000 亿美元增长到今天的 7400 亿美元，这也使其成为一个潜在的股票分拆股。</p>
<p>但作为投资者，我们关心的是未来几年礼来的股价走势，以及未来 3 到 5 年甚至更长时间内的发展。</p>
<p>这就是为什么 24/7 华尔街会关注预期收入和净收入，为您提供我们对未来股价从 2025 年到 2030 年的最佳估计。</p>
<p>其他 “专家” 会查看过去的增长率，并根据过去的数字来确定未来的股价。然而，我们将为您解释我们的假设，并告诉您我们认为将推动礼来股票未来增长的关键因素。</p>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/10/imageForEntry31-0VG.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/10/imageForEntry31-0VG.jpg"/></p>
<h2><strong>礼来最近的股价成功</strong></h2>
<p>礼来股价在过去几年内飙升如此之多是如何做到的？让我们来看一下数据：</p>
<table>
<thead>
<tr>
<th></th>
<th>股价</th>
<th>收入 *</th>
<th>净收入 *</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016 年</td>
<td>$80.36</td>
<td>$21.22</td>
<td>$2.74</td>
</tr>
<tr>
<td>2017 年</td>
<td>$77.55</td>
<td>$19.94</td>
<td>($0.21)</td>
</tr>
<tr>
<td>2018 年</td>
<td>$122.13</td>
<td>$21.49</td>
<td>$3.23</td>
</tr>
<tr>
<td>2019 年</td>
<td>$140.83</td>
<td>$22.32</td>
<td>$8.32</td>
</tr>
<tr>
<td>2020 年</td>
<td>$206.46</td>
<td>$24.54</td>
<td>$6.19</td>
</tr>
<tr>
<td>2021 年</td>
<td>$238.31</td>
<td>$28.32</td>
<td>$5.58</td>
</tr>
<tr>
<td>2022 年</td>
<td>329.07</td>
<td>$28.54</td>
<td>$6.25</td>
</tr>
<tr>
<td>2023 年</td>
<td>$745.91</td>
<td>$34.12</td>
<td>$5.24</td>
</tr>
</tbody>
</table>
<p>* 收入和净收入以十亿计</p>
<p>自 2016 年以来，礼来的收入增长了 60%，但净收入增长了 91%。通常情况下，你不会期望一个公司的年收入增长率为 7% 时，股价会增长 828%，然而投资者对下一代药物的情绪推动了股价。</p>
<p>例如，2016 年，礼来的股价是过去 12 个月收益的 13 倍，市场每年增加了其估值，目前的市盈率为 125 倍。</p>
<p>这引发了一个合理的问题，礼来是否被高估，还是未来的收入将弥补昂贵的估值？</p>
<h2><strong>礼来股票的三大推动因素</strong></h2>
<ol>
<li><strong>创新药物管线</strong>：当前的药物管线中有几种在开发中具有很高潜力的药物。心脏代谢类别中的 Mounjaro、Zepbound 和 Jardiance，免疫学中的 Taltz 以及肿瘤学中的 Verzenio 是礼来未来增长的关键。虽然前述是较为安全的选择，但公司还有一些其他药物可能具有巨大的潜力。</li>
</ol>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2021/11/imageForEntry14-5mH.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2021/11/imageForEntry14-5mH.jpg"/></p>
<h2><strong>2025 年礼来（LLY）股价预测</strong></h2>
<p>目前华尔街对礼来股票的一年目标价为 898 美元，比今天的 848.90 美元高出 5.78%。</p>
<p>在 26 位分析师中，目前对礼来股票的评级为 1.71 或 “表现优异”，一年目标价最高为 1100 美元，最低为 540.00 美元。</p>
<p><strong>24/7 华尔街</strong> 将其一年目标价设定为 1040 美元。通过查看其各部分的总和，我们看到礼来的各个部分的估值如下：</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>内分泌学</td>
<td>每股 735 美元</td>
</tr>
<tr>
<td>肿瘤学</td>
<td>每股 122 美元</td>
</tr>
<tr>
<td>心血管</td>
<td>每股 4 美元</td>
</tr>
<tr>
<td>神经科学</td>
<td>每股 16 美元</td>
</tr>
<tr>
<td>免疫学</td>
<td>每股 38 美元</td>
</tr>
<tr>
<td>其他和管线</td>
<td>每股 110 美元</td>
</tr>
<tr>
<td>现金</td>
<td>每股 17 美元</td>
</tr>
</tbody>
</table>
<h2><strong>2025 年至 2030 年礼来股价估算</strong></h2>
<p>对于未来几年礼来股价的估值，我们将查看预期收入和净收入，并通过分配市盈率来给出公司的市值的最佳估计。</p>
<table>
<thead>
<tr>
<th></th>
<th><strong>收入</strong></th>
<th><strong>净收入</strong></th>
<th><strong>每股收益</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2025 年</strong></td>
<td>$52.8</td>
<td>$17.29</td>
<td>19.11</td>
</tr>
<tr>
<td><strong>2026 年</strong></td>
<td>$62.5</td>
<td>$22.49</td>
<td>25.03</td>
</tr>
<tr>
<td><strong>2027 年</strong></td>
<td>$70.87</td>
<td>$27.12</td>
<td>30.39</td>
</tr>
<tr>
<td><strong>2028 年</strong></td>
<td>$80.68</td>
<td>$32.2</td>
<td>25.97</td>
</tr>
<tr>
<td><strong>2029 年</strong></td>
<td>$87.99</td>
<td>$36.45</td>
<td>40.58</td>
</tr>
<tr>
<td><strong>2030 年</strong></td>
<td>$96.67</td>
<td>$41.12</td>
<td>46.29</td>
</tr>
</tbody>
</table>
<p>* 报告的收入和净收入以十亿计</p>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2024/07/LLY-chart-7-18-1.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2024/07/LLY-chart-7-18-1.png"/></p>
<h2>2025 年礼来价格预测和预测：</h2>
<p><strong>目标价：</strong> $1140.00</p>
<p><strong>上涨空间：</strong> 35.12%</p>
<p>我们预计 2025 年礼来的市盈率为 60，每股收益为 19.11 美元，从而得出目标价为 1140.00 美元。这一预测基于收入强劲增长 18.37%，达到 528 亿美元，以及净收入扩张至 172.9 亿美元，延续了前几年的上升趋势。</p>
<h2>2026 年礼来价格预测和预测：</h2>
<p><strong>目标价：</strong> $1250.00</p>
<p><strong>上涨空间：</strong> 47.48%</p>
<p>对于 2026 年，我们预计市盈率为 50，每股收益为 25.03 美元，从而得出目标价为 1251.50 美元。这反映了收入强劲增长 18.37%，达到 625 亿美元，以及净收入增至 224.9 亿美元，推动了更高的每股收益。</p>
<h2>2027 年礼来价格预测和预测：</h2>
<p><strong>目标价：</strong> $1520.00</p>
<p><strong>上涨空间：</strong> 79.06%</p>
<p>2027 年，我们预计市盈率将保持在 50，每股收益增至 30.39 美元。这导致目标价为 1519.50 美元。持续的收入增长 13.39%，达到 708.7 亿美元，以及净收入扩张至 271.2 亿美元，证明了股价大幅增长的合理性。</p>
<h2>2028 年礼来价格预测和预测：</h2>
<p><strong>价格目标：</strong> $1300.00</p>
<p><strong>上涨空间：</strong> 53.02%</p>
<p>2028 年，预计每股收益为$25.97，市盈率为 50，我们预测股价将达到$1298.50。尽管预计每股收益增长略有下降，但净收入持续强劲增长至 322 亿美元，营收增长 13.84% 至 806.8 亿美元，使股价保持高估值。</p>
<h2>2029 年礼来股价预测和预测：</h2>
<p><strong>价格目标：</strong> $1623.00</p>
<p><strong>上涨空间：</strong> 91.28%</p>
<p>到 2029 年，我们预计礼来的每股收益将上升至$40.58，市盈率调整为 40。这给我们一个价格目标为$1623.20。持续的营收增长 9.06% 至 879.9 亿美元和净收入扩张至 364.5 亿美元支持这一更高的估值。</p>
<h2>2030 年礼来股价预测和预测：</h2>
<p><strong>价格目标：</strong> $1850.00</p>
<p><strong>上涨空间：</strong> 118.11%</p>
<p>到 2030 年，我们预计礼来的每股收益将上升至$46.29，市盈率调整为 40。这给我们一个价格目标为$1851.60。持续的营收增长 9.86% 至 966.7 亿美元和净收入扩张至 411.2 亿美元支持这一更高的估值。</p>
<table>
<thead>
<tr>
<th>年份</th>
<th>价格目标</th>
<th>与当前价格的变化百分比</th>
</tr>
</thead>
<tbody>
<tr>
<td>2025</td>
<td>$1146.60</td>
<td>上涨 35.12%</td>
</tr>
<tr>
<td>2026</td>
<td>$1251.50</td>
<td>上涨 47.48%</td>
</tr>
<tr>
<td>2027</td>
<td>$1519.50</td>
<td>上涨 79.06%</td>
</tr>
<tr>
<td>2028</td>
<td>$1298.50</td>
<td>上涨 53.02%</td>
</tr>
<tr>
<td>2029</td>
<td>$1623.20</td>
<td>上涨 91.28%</td>
</tr>
<tr>
<td>2030</td>
<td>$1851.60</td>
<td>上涨 118.19%</td>
</tr>
</tbody>
</table>
<h2>“下一个英伟达” 可能改变你的生活</h2>
<p>如果你错过了英伟达的历史性飙升，那么从人工智能中获得改变生活的利润的机会并未结束。</p>
<p>2009 年首次预测到英伟达人工智能崛起的 24/7 华尔街分析师刚刚发布了一份名为 “下一个英伟达” 的全新研究报告。</p>
<p>点击这里下载您的免费副本。</p>
<p>这篇文章最初发表在 24/7 华尔街，关于礼来（LLY）股价预测和 2025-2030 年展望。</p>

礼来

<p>礼来（Eli Lilly）的股价自 2020 年以来稳步上涨，增长了 553%，目前交易价为 848.74 美元。公司的市值也从 1000 亿美元增长到 7400 亿美元。分析师预测礼来未来将表现积极，预计从 2025 年到 2030 年的营收和净利润。公司的成功归功于其创新药物管线、战略收购和运营效率。目前礼来股票的共识价格目标为 898 美元，一些分析师预测目标甚至更高</p>

<p>Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 553% and currently trading at $848.74.</p>
<div class="lb-trans"><p>自 2020 年初以来，礼来（NYSE: LLY）的股价图呈直线上升趋势，上涨了 553%，目前交易价为 848.74 美元。</p>
</div><p>The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years, Eli Lilly went from a $100 billion market capitalization to $740 billion today, which also makes it a potential stock split stock.</p>
<div class="lb-trans"><p>该公司成立于 1876 年，但直到 1952 年才上市，但在过去的 4 年中，礼来的市值从 1000 亿美元增长到今天的 7400 亿美元，这也使其成为一个潜在的股票分拆股。</p>
</div><p>But as investors, we care about the stock price years down the line, what Eli Lilly will do in the next 3 to 5 years and beyond.</p>
<div class="lb-trans"><p>但作为投资者，我们关心的是未来几年礼来的股价走势，以及未来 3 到 5 年甚至更长时间内的发展。</p>
</div><p>That is why 24/7 Wall Street looks at projected revenue and net income to give you our best estimate of future stock prices from 2025 to 2030.</p>
<div class="lb-trans"><p>这就是为什么 24/7 华尔街会关注预期收入和净收入，为您提供我们对未来股价从 2025 年到 2030 年的最佳估计。</p>
</div><p>Other “experts” look at past growth rates and assign future stock prices off those past numbers. However we will walk you through our assumptions and give you the key drivers we see propelling Eli Lilly stock in the future.</p>
<div class="lb-trans"><p>其他 “专家” 会查看过去的增长率，并根据过去的数字来确定未来的股价。然而，我们将为您解释我们的假设，并告诉您我们认为将推动礼来股票未来增长的关键因素。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/10/imageForEntry31-0VG.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2022/10/imageForEntry31-0VG.jpg"/></p>
<h2><strong>Eli Lilly’s Recent Stock Success</strong></h2>
<div class="lb-trans"><h2><strong>礼来最近的股价成功</strong></h2>
</div><p>How did Eli Lilly’ stock price soar so much in the past few years? Lets take a look at the numbers:</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Share Price</td>
<td>Revenues*</td>
<td>Net Income*</td>
</tr>
<tr>
<td>2016</td>
<td>$80.36</td>
<td>$21.22</td>
<td>$2.74</td>
</tr>
<tr>
<td>2017</td>
<td>$77.55</td>
<td>$19.94</td>
<td>($0.21)</td>
</tr>
<tr>
<td>2018</td>
<td>$122.13</td>
<td>$21.49</td>
<td>$3.23</td>
</tr>
<tr>
<td>2019</td>
<td>$140.83</td>
<td>$22.32</td>
<td>$8.32</td>
</tr>
<tr>
<td>2020</td>
<td>$206.46</td>
<td>$24.54</td>
<td>$6.19</td>
</tr>
<tr>
<td>2021</td>
<td>$238.31</td>
<td>$28.32</td>
<td>$5.58</td>
</tr>
<tr>
<td>2022</td>
<td>329.07</td>
<td>$28.54</td>
<td>$6.25</td>
</tr>
<tr>
<td>2023</td>
<td>$745.91</td>
<td>$34.12</td>
<td>$5.24</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><p>礼来股价在过去几年内飙升如此之多是如何做到的？让我们来看一下数据：</p>
<table>
<thead>
<tr>
<th></th>
<th>股价</th>
<th>收入 *</th>
<th>净收入 *</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016 年</td>
<td>$80.36</td>
<td>$21.22</td>
<td>$2.74</td>
</tr>
<tr>
<td>2017 年</td>
<td>$77.55</td>
<td>$19.94</td>
<td>($0.21)</td>
</tr>
<tr>
<td>2018 年</td>
<td>$122.13</td>
<td>$21.49</td>
<td>$3.23</td>
</tr>
<tr>
<td>2019 年</td>
<td>$140.83</td>
<td>$22.32</td>
<td>$8.32</td>
</tr>
<tr>
<td>2020 年</td>
<td>$206.46</td>
<td>$24.54</td>
<td>$6.19</td>
</tr>
<tr>
<td>2021 年</td>
<td>$238.31</td>
<td>$28.32</td>
<td>$5.58</td>
</tr>
<tr>
<td>2022 年</td>
<td>329.07</td>
<td>$28.54</td>
<td>$6.25</td>
</tr>
<tr>
<td>2023 年</td>
<td>$745.91</td>
<td>$34.12</td>
<td>$5.24</td>
</tr>
</tbody>
</table>
</div><p>*Revenue and Net Income in Billions</p>
<div class="lb-trans"><p>* 收入和净收入以十亿计</p>
</div><p>Since 2016, Eli Lilly’s revenue grew 60% but income grew by 91%. Typically you wouldn’t expect a company growing at its top line by 7% annually to see a 828% increase in share price, however investor sentiment for the next line of drugs front ran the stock price.</p>
<div class="lb-trans"><p>自 2016 年以来，礼来的收入增长了 60%，但净收入增长了 91%。通常情况下，你不会期望一个公司的年收入增长率为 7% 时，股价会增长 828%，然而投资者对下一代药物的情绪推动了股价。</p>
</div><p>For example, in 2016 Eli Lilly was trading 13 times the trailing 12 months earnings and the market has increased its valuation each year and currently trades at a 125 times earnings multiple.</p>
<div class="lb-trans"><p>例如，2016 年，礼来的股价是过去 12 个月收益的 13 倍，市场每年增加了其估值，目前的市盈率为 125 倍。</p>
</div><p>This raises the valid question, is Eli Lilly overvalued or will future revenues make up for the expensive valuation?</p>
<div class="lb-trans"><p>这引发了一个合理的问题，礼来是否被高估，还是未来的收入将弥补昂贵的估值？</p>
</div><h2><strong>3 Key Drivers of Eli Lilly Stock</strong></h2>
<ol>
<li><strong>Innovated Drug Pipeline</strong>: The current drug pipeline is loaded with several very high potential drugs in development. Mounjaro, Zepbound and Jardiance in the cardiometabolic category, Taltz in immunology and Verzenio in oncology are the future of Eli Lilly’s growth. While the aforementioned are the safer bets, the company has a handful of other drugs that could hold blockbuster potential.</li>
<li><strong>Strategic Acquisitions</strong>: The acquisition of Morphic, with its promising drug candidate MORF-057, is a testament to Lilly’s strategic vision. This drug, if successful in late-stage trials, could become a major success in the treatment of inflammatory bowel disease (IBD). Lilly’s focus on acquiring mid-sized companies (13 since 2020) with promising pipelines has bolstered its own research and development efforts, positioning it well for future growth.</li>
<li><strong>Operational Efficiency:</strong> With a sound balance sheet, Eli Lilly should continue to improve operational efficiency and manage costs to have net income growth rates above revenue growth.</li>
</ol>
<div class="lb-trans"><h2><strong>礼来股票的三大推动因素</strong></h2>
<ol>
<li><strong>创新药物管线</strong>：当前的药物管线中有几种在开发中具有很高潜力的药物。心脏代谢类别中的 Mounjaro、Zepbound 和 Jardiance，免疫学中的 Taltz 以及肿瘤学中的 Verzenio 是礼来未来增长的关键。虽然前述是较为安全的选择，但公司还有一些其他药物可能具有巨大的潜力。</li>
</ol>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2021/11/imageForEntry14-5mH.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2021/11/imageForEntry14-5mH.jpg"/></p>
<h2><strong>Eli Lilly (LLY) Stock Price Prediction in 2025</strong></h2>
<div class="lb-trans"><h2><strong>2025 年礼来（LLY）股价预测</strong></h2>
</div><p>The current Wall Street consensus 1 year price target of Eli Lilly stock is $898, which is 5.78 % higher than the today’s price of $848.90</p>
<div class="lb-trans"><p>目前华尔街对礼来股票的一年目标价为 898 美元，比今天的 848.90 美元高出 5.78%。</p>
</div><p>Of the 26 analysts covering Eli Lilly stock, the current rating is 1.71 or “Outperform” with 1 year price targets as high as $1,100 and as low as $540.00.</p>
<div class="lb-trans"><p>在 26 位分析师中，目前对礼来股票的评级为 1.71 或 “表现优异”，一年目标价最高为 1100 美元，最低为 540.00 美元。</p>
</div><p><strong>24/7 Wall Street’s</strong> sets its 1 year price target at $1,040. Taking a look at the sum of its parts, we see Eli Lilly’s vertices valued as following:</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Endocrinology</td>
<td>$735/ share</td>
</tr>
<tr>
<td>Oncology</td>
<td>$122/ Share</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>$4/ Share</td>
</tr>
<tr>
<td>Neuroscience</td>
<td>$16/ Share</td>
</tr>
<tr>
<td>Immunology</td>
<td>$38/ Share</td>
</tr>
<tr>
<td>Others and Pipeline</td>
<td>$110/ Share</td>
</tr>
<tr>
<td>Cash</td>
<td>$17/ Share</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><p><strong>24/7 华尔街</strong> 将其一年目标价设定为 1040 美元。通过查看其各部分的总和，我们看到礼来的各个部分的估值如下：</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>内分泌学</td>
<td>每股 735 美元</td>
</tr>
<tr>
<td>肿瘤学</td>
<td>每股 122 美元</td>
</tr>
<tr>
<td>心血管</td>
<td>每股 4 美元</td>
</tr>
<tr>
<td>神经科学</td>
<td>每股 16 美元</td>
</tr>
<tr>
<td>免疫学</td>
<td>每股 38 美元</td>
</tr>
<tr>
<td>其他和管线</td>
<td>每股 110 美元</td>
</tr>
<tr>
<td>现金</td>
<td>每股 17 美元</td>
</tr>
</tbody>
</table>
</div><h2><strong>Eli Lilly’s Share Price Estimates 2025-2030</strong></h2>
<div class="lb-trans"><h2><strong>2025 年至 2030 年礼来股价估算</strong></h2>
</div><p>Valuing Eli Lilly’s stock price for the coming years, we will take a look at expected revenue and net income and give our best estimate at the market value of the company by assigning a price to earnings multiple.</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Revenue</strong></td>
<td><strong>Net Income</strong></td>
<td><strong>EPS</strong></td>
</tr>
<tr>
<td><strong>2025</strong></td>
<td>$52.8</td>
<td>$17.29</td>
<td>19.11</td>
</tr>
<tr>
<td><strong>2026</strong></td>
<td>$62.5</td>
<td>$22.49</td>
<td>25.03</td>
</tr>
<tr>
<td><strong>2027</strong></td>
<td>$70.87</td>
<td>$27.12</td>
<td>30.39</td>
</tr>
<tr>
<td><strong>2028</strong></td>
<td>$80.68</td>
<td>$32.2</td>
<td>25.97</td>
</tr>
<tr>
<td><strong>2029</strong></td>
<td>$87.99</td>
<td>$36.45</td>
<td>40.58</td>
</tr>
<tr>
<td><strong>2030</strong></td>
<td>$96.67</td>
<td>$41.12</td>
<td>46.29</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><p>对于未来几年礼来股价的估值，我们将查看预期收入和净收入，并通过分配市盈率来给出公司的市值的最佳估计。</p>
<table>
<thead>
<tr>
<th></th>
<th><strong>收入</strong></th>
<th><strong>净收入</strong></th>
<th><strong>每股收益</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2025 年</strong></td>
<td>$52.8</td>
<td>$17.29</td>
<td>19.11</td>
</tr>
<tr>
<td><strong>2026 年</strong></td>
<td>$62.5</td>
<td>$22.49</td>
<td>25.03</td>
</tr>
<tr>
<td><strong>2027 年</strong></td>
<td>$70.87</td>
<td>$27.12</td>
<td>30.39</td>
</tr>
<tr>
<td><strong>2028 年</strong></td>
<td>$80.68</td>
<td>$32.2</td>
<td>25.97</td>
</tr>
<tr>
<td><strong>2029 年</strong></td>
<td>$87.99</td>
<td>$36.45</td>
<td>40.58</td>
</tr>
<tr>
<td><strong>2030 年</strong></td>
<td>$96.67</td>
<td>$41.12</td>
<td>46.29</td>
</tr>
</tbody>
</table>
</div><p>*Revenue and net income reported in billions</p>
<div class="lb-trans"><p>* 报告的收入和净收入以十亿计</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2024/07/LLY-chart-7-18-1.png" alt="" original-src="https://247wallst.com/wp-content/uploads/2024/07/LLY-chart-7-18-1.png"/></p>
<h2>Eli Lilly Price Forecast and Prediction for 2025:</h2>
<div class="lb-trans"><h2>2025 年礼来价格预测和预测：</h2>
</div><p><strong>Price Target:</strong> $1140.00</p>
<p><strong>Upside:</strong> 35.12%</p>
<p>We expect Eli Lilly’s P/E ratio in 2025 to be 60 with an EPS of $19.11, resulting in a price target of $1140.00 This prediction is based on strong revenue growth of 18.37% to $52.80 billion and net income expansion to $17.29 billion, continuing the upward trajectory from previous years.</p>
<div class="lb-trans"><p><strong>目标价：</strong> $1140.00</p>
<p><strong>上涨空间：</strong> 35.12%</p>
<p>我们预计 2025 年礼来的市盈率为 60，每股收益为 19.11 美元，从而得出目标价为 1140.00 美元。这一预测基于收入强劲增长 18.37%，达到 528 亿美元，以及净收入扩张至 172.9 亿美元，延续了前几年的上升趋势。</p>
</div><h2>Eli Lilly Price Forecast and Prediction for 2026:</h2>
<div class="lb-trans"><h2>2026 年礼来价格预测和预测：</h2>
</div><p><strong>Price Target:</strong> $1250.00</p>
<p><strong>Upside:</strong> 47.48%</p>
<p>For 2026, we anticipate a P/E ratio of 50 with an EPS of $25.03, leading to a price target of $1251.50. This reflects significant revenue growth of 18.37% to $62.50 billion and an increase in net income to $22.49 billion, driving higher earnings per share.</p>
<div class="lb-trans"><p><strong>目标价：</strong> $1250.00</p>
<p><strong>上涨空间：</strong> 47.48%</p>
<p>对于 2026 年，我们预计市盈率为 50，每股收益为 25.03 美元，从而得出目标价为 1251.50 美元。这反映了收入强劲增长 18.37%，达到 625 亿美元，以及净收入增至 224.9 亿美元，推动了更高的每股收益。</p>
</div><h2>Eli Lilly Price Forecast and Prediction for 2027:</h2>
<div class="lb-trans"><h2>2027 年礼来价格预测和预测：</h2>
</div><p><strong>Price Target:</strong> $1520.00</p>
<p><strong>Upside:</strong> 79.06%</p>
<p>In 2027, we project the P/E ratio to remain at 50, with EPS increasing to $30.39. This results in a price target of $1519.50. Continued revenue growth of 13.39% to $70.87 billion and net income expansion to $27.12 billion justifies this substantial increase in stock price.</p>
<div class="lb-trans"><p><strong>目标价：</strong> $1520.00</p>
<p><strong>上涨空间：</strong> 79.06%</p>
<p>2027 年，我们预计市盈率将保持在 50，每股收益增至 30.39 美元。这导致目标价为 1519.50 美元。持续的收入增长 13.39%，达到 708.7 亿美元，以及净收入扩张至 271.2 亿美元，证明了股价大幅增长的合理性。</p>
</div><h2>Eli Lilly Price Forecast and Prediction for 2028:</h2>
<div class="lb-trans"><h2>2028 年礼来价格预测和预测：</h2>
</div><p><strong>Price Target:</strong> $1300.00</p>
<p><strong>Upside:</strong> 53.02%</p>
<p>With an EPS of $25.97 and a P/E ratio of 50 in 2028, we forecast the stock price to be $1298.50. The slight dip in EPS growth is expected, but sustained strong performance in net income to $32.20 billion and revenue growth of 13.84% to $80.68 billion keeps the stock highly valued.</p>
<div class="lb-trans"><p><strong>价格目标：</strong> $1300.00</p>
<p><strong>上涨空间：</strong> 53.02%</p>
<p>2028 年，预计每股收益为$25.97，市盈率为 50，我们预测股价将达到$1298.50。尽管预计每股收益增长略有下降，但净收入持续强劲增长至 322 亿美元，营收增长 13.84% 至 806.8 亿美元，使股价保持高估值。</p>
</div><h2>Eli Lilly Price Forecast and Prediction for 2029:</h2>
<div class="lb-trans"><h2>2029 年礼来股价预测和预测：</h2>
</div><p><strong>Price Target:</strong> $1623.00</p>
<p><strong>Upside:</strong> 91.28%</p>
<p>By 2029, we estimate Eli Lilly’s EPS to rise to $40.58, with the P/E ratio adjusting to 40. This gives us a price target of $1623.20. The continuous revenue growth of 9.06% to $87.99 billion and net income expansion to $36.45 billion supports this higher valuation.</p>
<div class="lb-trans"><p><strong>价格目标：</strong> $1623.00</p>
<p><strong>上涨空间：</strong> 91.28%</p>
<p>到 2029 年，我们预计礼来的每股收益将上升至$40.58，市盈率调整为 40。这给我们一个价格目标为$1623.20。持续的营收增长 9.06% 至 879.9 亿美元和净收入扩张至 364.5 亿美元支持这一更高的估值。</p>
</div><h2>Eli Lilly Price Forecast and Prediction for 2030:</h2>
<div class="lb-trans"><h2>2030 年礼来股价预测和预测：</h2>
</div><p><strong>Price Target:</strong> $1850.00</p>
<div class="lb-trans"><p><strong>价格目标：</strong> $1850.00</p>
</div><p><strong>Upside:</strong> 118.11%</p>
<p>By 2030, we estimate Eli Lilly’s EPS to rise to $46.29, with the P/E ratio adjusting to 40. This gives us a price target of $1851.60. The continuous revenue growth of 9.86% to $96.67 billion and net income expansion to $41.12 billion supports this higher valuation.</p>
<table>
<thead>
<tr>
<th>Year</th>
<th>Price Target</th>
<th>% Change From Current Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>2025</td>
<td>$1146.60</td>
<td>Upside of 35.12%</td>
</tr>
<tr>
<td>2026</td>
<td>$1251.50</td>
<td>Upside of 47.48%</td>
</tr>
<tr>
<td>2027</td>
<td>$1519.50</td>
<td>Upside of 79.06%</td>
</tr>
<tr>
<td>2028</td>
<td>$1298.50</td>
<td>Upside of 53.02%</td>
</tr>
<tr>
<td>2029</td>
<td>$1623.20</td>
<td>Upside of 91.28%</td>
</tr>
<tr>
<td>2030</td>
<td>$1851.60</td>
<td>Upside of 118.19%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><p><strong>上涨空间：</strong> 118.11%</p>
<p>到 2030 年，我们预计礼来的每股收益将上升至$46.29，市盈率调整为 40。这给我们一个价格目标为$1851.60。持续的营收增长 9.86% 至 966.7 亿美元和净收入扩张至 411.2 亿美元支持这一更高的估值。</p>
<table>
<thead>
<tr>
<th>年份</th>
<th>价格目标</th>
<th>与当前价格的变化百分比</th>
</tr>
</thead>
<tbody>
<tr>
<td>2025</td>
<td>$1146.60</td>
<td>上涨 35.12%</td>
</tr>
<tr>
<td>2026</td>
<td>$1251.50</td>
<td>上涨 47.48%</td>
</tr>
<tr>
<td>2027</td>
<td>$1519.50</td>
<td>上涨 79.06%</td>
</tr>
<tr>
<td>2028</td>
<td>$1298.50</td>
<td>上涨 53.02%</td>
</tr>
<tr>
<td>2029</td>
<td>$1623.20</td>
<td>上涨 91.28%</td>
</tr>
<tr>
<td>2030</td>
<td>$1851.60</td>
<td>上涨 118.19%</td>
</tr>
</tbody>
</table>
</div><h2>“The Next NVIDIA” Could Change Your Life</h2>
<div class="lb-trans"><h2>“下一个英伟达” 可能改变你的生活</h2>
</div><p>If you missed out on NVIDIA’s historic run, your chance to see life-changing profits from AI isn’t over.</p>
<div class="lb-trans"><p>如果你错过了英伟达的历史性飙升，那么从人工智能中获得改变生活的利润的机会并未结束。</p>
</div><p>The 24/7 Wall Street Analyst who first called NVIDIA’s AI-fueled rise in 2009 just published a brand-new research report named “The Next NVIDIA.”</p>
<div class="lb-trans"><p>2009 年首次预测到英伟达人工智能崛起的 24/7 华尔街分析师刚刚发布了一份名为 “下一个英伟达” 的全新研究报告。</p>
</div><p>Click here to download your FREE copy.</p>
<div class="lb-trans"><p>点击这里下载您的免费副本。</p>
</div><p>The post Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030 appeared first on 24/7 Wall St..</p>
<div class="lb-trans"><p>这篇文章最初发表在 24/7 华尔街，关于礼来（LLY）股价预测和 2025-2030 年展望。</p>
</div>

礼来（LLY）股票价格预测和展望 2025-2030